01999nas a2200217   4500000000100000008004100001260001200042653002500054653003100079653004900110653001900159653002600178100001500204700002400219700001500243245008000258856008900338300000900427520133100436022001401767       2023                            d  c06/202310aAutonomic neuropathy10aGuillain–Barré syndrome10aHIV-associated distal sensory polyneuropathy10aHansen disease10aVasculitic neuropathy1 aDe León A1 aGarcia-Santibanez R1 aHarrison T00aArticle Topic: Neuropathies Due to Infections and Antimicrobial Treatments.  uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10256960/pdf/11940_2023_Article_756.pdf  a1-173 a<p><strong>Purpose of Review: </strong>The aim of this review is to discuss the presentation, diagnosis, and management of polyneuropathy (PN) in selected infections. Overall, most infection related PNs are an indirect consequence of immune activation rather than a direct result of peripheral nerve infection,&nbsp; Schwann cell infection, or toxin production, though&nbsp;note this review will describe infections that cause PN through all these mechanisms. Rather than dividing them by each infectious agent separately, we have grouped the infectious neuropathies according to their presenting phenotype, to serve as a guide to clinicians. Finally, toxic neuropathies related to antimicrobials are briefly summarized.</p>

<p><strong>Recent findings: </strong>While PN from many infections is decreasing, increasing evidence links infections to variants of GBS. Incidence of neuropathies secondary to use of HIV therapy has decreased over the last few years.</p>

<p><strong>Summary: </strong>In this manuscript, a general overview of the more common infectious causes of PN will be discussed, dividing them across clinical phenotypes: large- and small-fiber polyneuropathy, Guillain-Barré syndrome (GBS), mononeuritis multiplex, and autonomic neuropathy. Rare but important infectious causes are also discussed.</p>
  a1092-8480